Results 211 to 220 of about 54,594 (319)

Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia.

Blood
Ren H, Elliott N, Lye B, Sharif Shohan MU, Cross JW, Field L, Ponnusamy K, Rice S, Jackson T, Leontari I, El Ouazzani N, Thomas R, Inglott S, Bartram J, Smith O, Bond J, Roberts IAG, Halsey C, Bashford-Rogers R, Milne TA, Roy A, Karadimitris A.   +21 more
europepmc   +1 more source

Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: mechanisms of action, adverse effects, and future perspectives. [PDF]

Front Immunol
Lopatnikova JA, Sennikov SV.
europepmc   +1 more source

Multiformat T‐Cell‐Engaging Bispecific Antibodies Targeting Human Breast Cancers [PDF]

, 2015
Yu Cao, Jun Y. Axup, S. Y. Jennifer, Rongsheng E. Wang, Seihyun Choi, Virginie Tardif, Reyna K. V. Lim, Holly Pugh, Brian R. Lawson, Gus Welzel, Stephanie A. Kazane, Ying Sun, Feng Tian, Shailaja Srinagesh, Tsotne Javahishvili, Peter G. Schultz, Chan Hyuk Kim   +16 more
openalex   +1 more source

Bispecific biologics rush [PDF]

Nature Biotechnology, 2011
openaire   +1 more source

Quantitative Prediction of Human Pharmacokinetics for Fc‐Engineered Therapeutic Monoclonal Antibodies With Increased FcRn Binding Mutations After Subcutaneous Injection

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Fc‐engineered antibodies (mAbs) enhancing FcRn binding have rapidly expanded in drug discovery and development. Although an approach exists for predicting the pharmacokinetics of Fc‐engineered mAbs after intravenous injections in humans, no methodology has been established for predicting pharmacokinetics after subcutaneous injections.
Kenta Haraya, Taichi Kuramochi
wiley   +1 more source

Bispecific antibodies and CAR T cells targeting a TP53 mutation-associated neoantigen show discordant affinity requirements. [PDF]

J Clin Invest
DiNapoli SR, Wright KM, Mog BJ, Pearlman AH, Nichakawade TD, Marcou N, Hsiue EH, Hwang MS, Douglass J, Liu Q, Watson E, Dal Molin M, Cohen JD, Popoli M, Paul S, Konig MF, Wyhs N, Azurmendi PA, Glavaris S, Ge J, Awosika TO, Liu J, Gabrielson KL, Gabelli SB, Pardoll DM, Bettegowda C, Papadopoulos N, Kinzler KW, Zhou S, Vogelstein B.   +29 more
europepmc   +1 more source

Figure S8 from A Novel Designed Anti–PD-L1/OX40 Bispecific Antibody Augments Both Peripheral and Tumor-Associated Immune Responses for Boosting Antitumor Immunity

Baocun Li, Shiyong Gong, Nianying Zhang, Beilei Shi, Zhou Lv, Yu Zhang, Naren Gaowa, Liqin Dong, Danqing Wu, Jianfu Wu, Fan Liu, Rui Zhang, Ramin Behzadigohar, Vinod Ganju, Chengbin Wu, Xuan Wu   +15 more
openalex   +1 more source

Primary Cutaneous B‐Cell Lymphomas: An Updated Portrait of Classification, Biology, and Clinical Management

European Journal of Haematology, Volume 116, Issue 2, Page 116-128, February 2026.
ABSTRACT Primary cutaneous B‐cell lymphomas (CBCL) represent a clinically and biologically heterogeneous group of extranodal non‐Hodgkin lymphomas confined to the skin at the time of diagnosis. They account for approximately 25% of all primary cutaneous lymphomas and are subclassified into distinct entities according to the World Health Organization ...
A. Bernardelli, E. Carazzai, B. Bugnotto, F. Bellinato, M. Krampera, C. Visco   +5 more
wiley   +1 more source

Application of Membrane Materials in Bioseparation and Downstream Processing. [PDF]

Membranes (Basel)
Zhang W, Kong L.
europepmc   +1 more source

AMCP Market Insights: Managed care approaches to bispecific antibodies with a focus on follicular lymphoma and diffuse large B-cell lymphoma

Bridget Flavin, Denise Wolff, Laura Rose Bobolts, Tara Graff, Kirollos S. Hanna, Ryan Haumschild, Timothy Mok, Bhavesh Shah   +7 more
openalex   +2 more sources